+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Peptide Synthesis Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987037
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • AAPPTec
  • Anaspec Inc
  • Bachem Holding AG
  • Biotage AB
  • CEM Corporation
  • CSBio Company Inc
  • MORE
The peptide synthesis market studied was anticipated to grow with a CAGR of nearly 12.5% during the forecast period. The major factors attributing to the growth of the market is a steep rise in the adoption of peptides in pharmaceutical and consumer healthcare industries owing to their wide range of applications in the treatment of various lifestyle disorders such as cancers, diabetes, and obesity. For instance, according to the International Diabetes Federation report published in 2019, around 463 million people are living with diabetes and Type 2 diabetes is the most common type of diabetes, accounting for around 90% of all diabetes globally. Thus, due to rise in the volume of patient pool with Type 2 diabetes, the demand for peptides is increasing owing to the available peptide medications such as dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) analogs, etc to synthesize the efficient medication for these ailments is likely to fuel the market over the forecast period. Also, the increased research activities due to the rise in funding for R&D, and the advantages of advanced peptide synthesizers available in the can further boost the growth of the peptide synthesis market throughout the period.

Key Market Trends

The Solid Phase Synthesis by Technology Segment is Expected to Hold the Largest Market Share in the Peptide Synthesis Market
  • The solid-phase synthesis is expected to account for the largest revenue over the forecast period as it is the most common method of synthesis in chemicals and biopharmaceutical industries. This dominance is due to the wide range of advantages such as high-level automation, ease of operation in GMP manufacturing, easy purification in API process development with short production cycles, and ability to synthesize long peptides with a smaller amount of amino acids. Thus, owing to several distinct advantages over the liquid-phase procedure, the growth of the segment is expected to drive the market revenue over the forecast period.
  • Based on the end-user, pharmaceutical & biotechnology companies continue to dominate the market owing to the steep rise of peptide therapeutics industry because of their cost-effectiveness, enhanced efficiency with lower toxicity and ongoing drug development activities in life science research. On the other hand, the contract development and manufacturing organizations witness the highest CAGR throughout the forecast period owing to the advancements in the synthesizers, quality control, and reagents driving the segment and contribute to the growth of the global market.
North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall peptide synthesis market throughout the forecast period. The dominance is due to the growing prevalence of obesity with a rise in sedentary deskbound lifestyle and lack of proper diet along with physical activity resulting in various chronic diseases like diabetes in the United States necessitated the efficient treatment. For instance, according to the International Diabetes Federation in 2019, about 48 million adults in North America are living with diabetes and are expected to continue resulting in higher demand for peptide therapeutics driving the market in the region.

Furthermore, the increased availability of advanced healthcare infrastructure along with huge investments by the key players in this region to develop a new peptide synthesis technologies is also likely to fuel the market growth. Also, a favorable earlier approval of peptide drugs owing to the accelerated drug approval initiative by USFDA is also likely to fuel the market growth in this region across the forecast period contributing to its outstanding market share in the global peptide synthesis market.

Competitive Landscape

The peptide synthesis market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, research collaboration, while others are introducing new products to maintain their market share. For Instance, In May 2019, CEM Corporation launched Liberty PRO, the world’s first-ever large-scale automated microwave peptide synthesizer. The system can synthesize 1 kg of crude peptide per batch utilizing reaction vessel, sizes up to 15 liters with unmatched purity, speed, and waste reduction fueling the market revenue share. Few of the major players currently dominating the industry in terms of revenue are AAPPTec, CSBio Company Inc, Biotage AB, Bachem Holding AG, and CEM Corporation.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5


  • AAPPTec
  • Anaspec Inc
  • Bachem Holding AG
  • Biotage AB
  • CEM Corporation
  • CSBio Company Inc
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study




4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Investments Along with Huge Funding for R&D of Genomics and Proteomics in Bio-pharmaceutical Industry
4.2.2 Rapid Technological Advancements in Peptide synthesizers Coupled by Strong Peptide Therapeutics Pipeline
4.3 Market Restraints
4.3.1 Issues Pertaining to Large-scale Peptide Synthesis and Lack of Robust Distribution Network
4.3.2 Challenges in Development of Proper Route of Administration of Peptide Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5.1 Technology
5.1.1 Solid-Phase
5.1.2 Liquid-Phase
5.1.3 Hybrid & Recombinant
5.2 Product
5.2.1 Equipment
5.2.2 Reagents & Consumables
5.2.3 Others
5.3 End-User
5.3.1 Pharmaceutical & Biotechnology Companies
5.3.2 Contract Development & Manufacturing Organization (CDMO)
5.3.3 Academic & Research Institutes
5.4 Geography
5.4.1 North America United states Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles
6.1.1 AAPPTec
6.1.2 Anaspec Inc
6.1.3 Bachem Holding AG
6.1.4 Biotage AB
6.1.5 CEM Corporation
6.1.6 CSBio Company Inc
6.1.7 Gyros Protein Technologies AB
6.1.8 Merck KGaA
6.1.9 New England Peptide Inc
6.1.10 Thermo Fisher Scientific

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • AAPPTec
  • Anaspec Inc
  • Bachem Holding AG
  • Biotage AB
  • CEM Corporation
  • CSBio Company Inc
  • Gyros Protein Technologies AB
  • Merck KGaA
  • New England Peptide Inc
  • Thermo Fisher Scientific
Note: Product cover images may vary from those shown
5 of 5